Prostate cancer medicine hailed as a "milestone" breakthrough may not be available to every patient after a revision of the drug guidelines, according to the NHS.
Men in England who have already been treated with a new-generation cancer drug would not be eligible for Enzalutamide, according to the National Institute for Health and Care Excellence (Nice).
Nice, the public body which decides the cost-effectiveness of medicines for NHS patients, said the new drug should not be used by patients who had already taken abiraterone.
Enzalutamide blocks molecular signals driving prostate cancer and improved survival by 30% in men who had not undergone chemotherapy.
A further 80% of men with advanced cancer had the progression delayed, even if the tumour had failed to respond to other treatments.
More top news
Conservative and nationalist parties in Austria have reached a deal that will make 31-year-old Kurz Europe's youngest leader.
The Which? annual survey saw British Airways languishing near the bottom for passenger satisfaction in both short and long-haul.
The Orkney Islands took second place, followed by Rutland and Wychavon while last year's winner Winchester falls to fifth place.